IL-8, IL-10, TGF-𝜷, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment

Figure 2

Serum IL-10 levels of all study groups. The numbers of samples of the all groups are 14 for each. Group IA: severe persistent asthma patients before the treatment. Group IB: 4 months after the anti-IgE therapy, severe persistent asthma patients. Group IC: 18 months after the anti-IgE therapy, severe persistent asthma patients. Group II: newly diagnosed controlled allergic asthma patients. Group III: healthy individuals as control. 𝑃 values were as below: Group IA versus IB: 𝑃<0.0001, Group IA versus IC: 𝑃<0.0001, Group IA versus II: 𝑃<0.0001, Group IA versus Control: 𝑃<0.0001, Group IB versus IC: 𝑃=0.0024, Group IB versus Control: 𝑃<0.0001, Group IC versus Control: 𝑃=0.0018, and Group II versus Control: 𝑃<0.0001.